Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Globe Newswire•07/10/2026•08:48 ET
0
Key Highlights
- ➤Artelo selected for first BIO-Europe 2026 company presentation on November 10
- ➤ART26.12 Phase 1 study showed favorable safety and linear pharmacokinetics
- ➤ART26.12 demonstrated dosing flexibility under fasted and fed conditions
- ➤ART26.12 reduced osteoarthritis pain comparably to naproxen in nonclinical study
- ➤Artelo plans partnering discussions spanning pain, cancer cachexia, and obesity
Expert Statements
Andrew Yates, Senior Vice President and Chief Scientific Officer of Artelo Biosciences
“BIO-Europe brings together many of the organizations that are actively searching for differentiated programs in the areas where we are generating data.”
Andrew Yates, Senior Vice President and Chief Scientific Officer of Artelo Biosciences
“While we are grateful to feature our clinical experience with the first selective FABP5 inhibitor to enter the clinic, we also expect to advance our business development outreach with interested potential partners during BIO-Europe, and to show the breadth of what we have built across our wider portfolio in pain, cancer cachexia, and obesity.”
Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications
BIO-Europe provides a key platform to advance ongoing discussions and expand partnering opportunities across Artelo’s growing portfolio
Get started
Create a free account to read the full story.